Organogenesis (NASDAQ:ORGO) Shares Down 3.7% on Insider Selling

Shares of Organogenesis (NASDAQ:ORGO) dropped 3.7% on Friday following insider selling activity. The stock traded as low as $5.50 and last traded at $5.5550. Approximately 209,215 shares changed hands during trading, a decline of 86% from the average daily volume of 1,449,700 shares. The stock had previously closed at $5.77.

Specifically, Director Glenn H. Nussdorf sold 200,000 shares of the company’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $5.14, for a total value of $1,028,000.00. Following the completion of the sale, the director directly owned 2,565,591 shares of the company’s stock, valued at $13,187,137.74. This represents a 7.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Analyst Ratings Changes

Several analysts have recently commented on the company. BTIG Research reissued a “buy” rating and issued a $9.00 price target on shares of Organogenesis in a report on Monday. Wall Street Zen upgraded shares of Organogenesis from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Organogenesis in a report on Monday. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Organogenesis presently has an average rating of “Hold” and an average target price of $8.00.

Organogenesis Stock Performance

The company has a current ratio of 3.32, a quick ratio of 2.88 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $703.72 million, a PE ratio of -46.29 and a beta of 1.47. The stock’s 50 day moving average price is $4.85 and its two-hundred day moving average price is $4.49.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.07 by $0.11. The company had revenue of $150.86 million during the quarter, compared to the consensus estimate of $134.10 million. Organogenesis had a positive return on equity of 4.01% and a negative net margin of 1.30%. On average, equities analysts expect that Organogenesis will post -0.07 earnings per share for the current year.

Institutional Investors Weigh In On Organogenesis

A number of hedge funds and other institutional investors have recently modified their holdings of ORGO. Vanguard Group Inc. raised its holdings in shares of Organogenesis by 23.4% during the 1st quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company’s stock valued at $19,144,000 after buying an additional 841,618 shares during the period. Invesco Ltd. lifted its position in shares of Organogenesis by 779.7% during the first quarter. Invesco Ltd. now owns 1,069,252 shares of the company’s stock worth $4,619,000 after purchasing an additional 947,705 shares in the last quarter. Nuveen LLC purchased a new position in shares of Organogenesis in the first quarter valued at $742,000. Russell Investments Group Ltd. purchased a new stake in Organogenesis during the 1st quarter worth $547,000. Finally, American Century Companies Inc. boosted its position in Organogenesis by 32.7% in the 1st quarter. American Century Companies Inc. now owns 131,220 shares of the company’s stock valued at $567,000 after buying an additional 32,328 shares during the last quarter. 49.57% of the stock is currently owned by hedge funds and other institutional investors.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.